Shots:

• The approval is based on P-III EORTC1325/KEYNOTE-054 trial results assessing Keytruda (pembrolizumab-200mg- q3w) vs PBO in 1019 patients in the ratio (1:1) with completely resected stage IIIA- IIIB or IIIC melanoma for 1yr or until disease recurrence or unacceptable toxicity
• P-III EORTC1325/KEYNOTE-054 trial results: 43% reduction in the risk of disease recurrence or death; improvement in recurrence-free survival (RFS) benefit
• Keytruda (pembrolizumab) 100mg IV is a mAb- used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2- further activating T lymphocytes

Ref: Merck | Image: Merck